Loading…
Loading…
NTRR does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for NTRR and 80,000+ other tickers.
See exactly how NTRR's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for NTRR and 80,000+ other tickers.
Neutra Corp. specializes in the research, development, and provision of hemp-derived nutraceuticals. Its product portfolio features items such as CBD-infused sports creams, in addition to a variety of other health and wellness goods. Established in 2011, the company is headquartered in Sugar Land, Texas.
HOUSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Neutra Corp (OTC: NTRR), a company focused on health, wellness, and life sciences, today announced its forward-looking strategy for the third and fourth quarters of 2026, centered on deepening relationships with clinical trial sponsors and Contract Research Organizations (CROs). Neutra Corp has committed its full resources to the growth and expansion of Neutra Life Sciences, its wholly owned clinical research Site Management Organization (SMO) subsidiary, as the Company's primary strategic priority for the remainder of 2026 and beyond.
HOUSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Neutra Corp (OTC: NTRR), a company focused on health, wellness, and life sciences, today announced a series of operational milestones at its wholly owned subsidiary, Neutra Life Sciences, a clinical research Site Management Organization (SMO). Following its 2025 launch and early-stage growth, Neutra Life Sciences has proven its operational excellence with multiple clinical trial.
HOUSTON, TX, Dec. 29, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neutra Corporation (OTC PINK:NTRR), an emerging health and wellness research and development company, reflects on the 2023 year and plans for moving forward in 2024. In the previous press release, Neutra announced a medium-term management plan to meet the rapidly increasing demand for the company's modern approach to specialty health and wellness solutions.
HOUSTON, TX, Oct. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Neutra Corporation (OTC PINK: NTRR), an emerging health and wellness research and development company, announces today a two-year, medium-term management plan in order to meet the rapidly increasing demand for the company's modern approach to specialty health and wellness solutions. The strategic plan helps strengthen the shift towards the service business to grow its health and wellness portfolio and formalizes its pursuit of consulting services aimed at clinical research standards and education. The “Clinical Foundations” service model draws upon the multiple advances in the company's core products and will help cement its leadership of value creation in the specialty healthcare and wellness space.
KATY, TX / ACCESSWIRE / September 14, 2021 / Neutra Corp. subsidiary VIVIS has signed a groundbreaking letter of intent (LOI) with a Houston clinical research company that, if it comes to a successful conclusion, would lead to testing hemp-based cannabinoids to treat COVD-19. Under the LOI's provisions, VIVIS will now determine the feasibility of working with Mercury Clinical Research to start phase 1 clinical trial on CBD efficacies in combating SARS-COVID-2.